《大行報告》瑞信升中生製藥(01177.HK)評級至「跑贏大市」 目標價上調至13.2元
瑞信發表研究報告指,中生製藥(01177.HK)首季表現勝預期,在疫情影響之下收入及淨利仍增長0.2%及0.6%,分別已達到全年預測的23.7%及25.6%,相信公司最壞時期已過去。
該行指,展望未來疫情的影響正逐步減弱,期待中生的創新藥物將很快進入商業階段。其中,公司與康方生物-B(09926.HK)合作研發的PD-1單抗藥Penpulimab,用於治療經典霍奇金淋巴瘤的新藥申請料於明年上半年獲批,阿達木單抗Adalimumab的生物相似藥預期於明年推出。另外,肺癌新藥Anlotinib的專利組合也可能是未來增長主要動力。
瑞信將中生製藥的評級由「中性」上調至「跑贏大市」,目標價由11元調升至13.2元,將今年至2022年每股盈利預測上調2.68%、2.7%及5.29%,相信腫瘤藥業務未來增長將快過預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.